The AI-driven biotech has secured FDA alignment on a pivotal trial for its FAP therapy, with a study start planned for 2027.
This pharmaceutical-development technology company continues to demonstrate that its testing platform has real potential.
Recursion Pharmaceuticals, Inc. ( RXRX) announced Wednesday that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the design of its registrational Phase 3 trial of REC-4881 ...
Recursion announces FDA alignment for REC-4881’s Phase 3 trial in familial adenomatous polyposis, targeting crucial adenoma excision outcomes.
REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy ...
If you picked Recursion Pharmaceuticals for its AI-first pitch and deep pharma ties, the past year has probably felt rough.
Salt Lake City, UT, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering ...
In a Nov. 1 blog post, software engineer Nicolas Chagnet argues that Gleam pairs a simple functional syntax with the Erlang ...
In addition to that, given the crosstalk that is known between MAPK pathway and beta-catenin, MEK1/2 can also dampen some of the growth signals driven by APC loss. It is that platform insight that led ...
Google open-sourced Harness2, a recursive agent harnessing framework that lifted GLM-5 11.5 points on WorkBuddy-Bench with frozen weights.
Worker move goods for despatch in a redistribution centre of US online retail giant Amazon in Horn-Bad Meinberg, western Germany, on December 9, 2024. INA FASSBENDER/AFP via Getty Images Cloudflare's ...
Recursive self-improvement is already visible in large language models, but mostly in limited forms. Today's LLMs can revise answers, improve agent skills, write better prompts, generate training data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results